Abbott Slightly Raises Profit Forecast on Strong Medical Device Sales
(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong sales of its medical devices including its glucose-monitoring products.
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
4d
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...
We recently compiled a list of the Jim Cramer is Talking About These 14 Stocks Before Earnings. In this article, we are going ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback